Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

• Status: Terminated
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements. To date, there are no objective measures of these movements. The purpose of this study is to measure the reduction of the movements by amantadine and/or topiramate using an objective measure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Treatments: Amantadine; Topiramate

Criteria

Inclusion Criteria:

• Parkinson's Disease

• At least 21 years of age

• Must be taking Oral levodopa

• Must have dyskinesias by history or previous clinical observation

Exclusion Criteria:

• Significant cognitive impairment as measured by the Montreal Cognitive Assessment (MOCA) score of < 25

• Subjects with unstable medical or psychiatric conditions (including hallucinations)

• Use of dopamine receptor blocking medications (e.g., neuroleptics, certain antiemetics, tetrabenazine)

• History of unstable medical conditions (ie active cardiovascular disease, recent unwellness or surgery etc.)

• Use of anticoagulants

• Current substance abuse

• Previous adverse event on amantadine